TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02156154

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen
Study: NCT01841541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral of presumptive of TB cases by informal providers
Description: Training of informal providers to effectively refer TB suspects in the community to the primary health care system
Study: NCT02904538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotonic saline
Study: NCT03027908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride Toothpaste 1
Description: Toothpaste containing 1450 ppm F as Sodium Fluoride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Toothpaste 2
Description: Toothpaste containing 1450 ppm F as Sodium Fluoride
Study: NCT01816568

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SILS appendectomy
Description: Single incision laparoscopic appendectomy will be performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three port laparoscopic appendectomy
Description: Three port laparoscopic appendectomy will be performed
Study: NCT04060134

Intervention type: OTHER
Intervention: SimpliDerm HADM
Description: Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.

Intervention type: OTHER
Intervention: AlloDerm HADM
Description: Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.

Intervention type: OTHER
Intervention: AlloMax HADM
Description: Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.

Intervention type: OTHER
Intervention: FlexHD HADM
Description: Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.

Intervention type: OTHER
Intervention: DermACELL HADM
Description: Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
Study: NCT00480649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/ fluticasone propionate
Description: 2 active arms (parellel group)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/ fluticasone propionate
Description: 2 active arms (parellel group)
Study: NCT01758133

Intervention type: BEHAVIORAL
Intervention: Exposure to medical clown activities
Study: NCT00249015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
Study: NCT03883555

Intervention type: DEVICE
Intervention: High flow nasal therapy (HFNT) : Optiflow™
Description: HFNT will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs.~Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance

Intervention type: DEVICE
Intervention: Non invasive ventilation (niv)
Description: NIV will be delivered through a face mask connected to a dedicated ventilator with pressure support applied in a noninvasive ventilation mode (Monnal T75, Airliquide Medical Systems, Antony, France).~The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort.
Study: NCT01435824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human milk-dissolved amoxicillin
Description: An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of breast milk to have 100mL of a 50mg/mL suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Water-dissolved amoxicillin
Description: An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of water to have 100mL of a 50mg/mL suspension.
Study: NCT03327350

Intervention type: DEVICE
Intervention: WATCHMAN transplantation
Description: WATCHMAN Left Atrial Appendage System is a novel device designed to prevent the embolization of thrombi that may form in the LAA. It is hypothesized that it may prevent ischemic stroke and systemic

Intervention type: DRUG
Intervention: Oral anticoagulant drugs
Description: This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).For patients taking warfarin,international normalizedratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Followup visits occurred twice annually after the first year,with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected.
Study: NCT03084809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells+ FOLFOX4
Description: Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks. Collected CIK cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks.
Study: NCT01090817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSC) for infusion
Description: MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks
Study: NCT01961258

Intervention type: OTHER
Intervention: Computerized data base analysis and sampling of patients for outpatient clinic evaluation
Study: NCT03813225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral serratus Intercostal plane Block
Description: Will be performed by echo guided one puncture in the fifth costal arch with anterior axilary line, where the tip of the needle will be guided until it reaches a point above the external intercostal muscle, below the anterior serratus above the costal arch where they will be administered 21 ml of anesthesic mass, (20 ml of levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone.)
Study: NCT03716635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: 2.5c cold saline is used as a final flush after chemomechanical preparation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: normal saline
Description: a room temperature saline is used as a final flush after mechanical preparation
Study: NCT01143649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Subjects will be stimulated at 1 mA for 40 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Subjects will be stimulated at 1 mA for 40 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: Subjects will be stimulated at 1 mA for 40 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: Subjects will be stimulated at 1 mA for 40 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: constraint induced movement therapy (CIMT)
Study: NCT01845896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 4 m
Description: Oral alprazolam 4 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 4 m
Description: Oral alprazolam 4 mg + Inhaled placebo
Study: NCT04026620

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Informational Pamphlet
Description: The control group will be provided with two (2) informational pamphlets (and have it read to those who are of lower literacy). Pamphlets contain information about the harmful effects of drinking alcohol during pregnancy and the harmful effects of alcohol on the unborn baby.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Informational Pamphlet
Description: The control group will be provided with two (2) informational pamphlets (and have it read to those who are of lower literacy). Pamphlets contain information about the harmful effects of drinking alcohol during pregnancy and the harmful effects of alcohol on the unborn baby.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Motivational Enhancement Therapy (MET) Session
Description: The case control trial/efficacy study will provide a one-session MET session in Afrikaans (the predominant language of the region). The face-to-face session will provide information to help people and pregnant women who want to change their drinking behavior, become 'dry' and stay motivated to change their drinking behaviors. Sessions will be approximately one (1) hour and 30 minutes.
Study: NCT01137292

Intervention type: DRUG
Intervention: voriconazole (VFEND®)
Description: The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (\<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
Study: NCT00038103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib + Exemestane
Description: Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
Study: NCT03254394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Intravenous lidocaine will be dosed as a brief 1 mg/kg infusion (based on Ideal Body Weight (IBW)) over 10 minutes, followed by a 0.04 mg/kg/min infusion over additional 120 minutes, resulting in a total dose of 5.8 mg/kg IBW.~If this dose is tolerable in four consecutive sessions of mFOLFOX6 in six or more of the eight patients in the tolerability phase, we will initiate the randomized efficacy pilot study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose 5% in water will be administered as active comparator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFOX regimen
Description: Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days.
Study: NCT02116855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: according to the efficacy of AJBRs
Study: NCT01735474

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual technique
Description: A manual technique is employed in the intervention group based on passive movement and stretching of the respiratory system.~The manual technique includes:~stretching of diaphragm. Mobilization. Potentiation of the respiratory muscles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Usual care
Study: NCT01080131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Description: Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide 40 mg
Description: Triamcinolone acetonide 40 mg was supplied as a suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to canakinumab
Description: Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to triamcinolone acetonide
Description: Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
Study: NCT00387465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine 30mg/m2
Description: Azacitidine 30mg/m2 subcutaneously (SQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: 7mg by mouth (PO) on days 3 and 10 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: 7mg by mouth (PO) on days 3 and 10 of each cycle
Study: NCT01143649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: constraint induced movement therapy (CIMT)
Study: NCT04083196

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03472651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test treatment: flupentixol/melitracen
Description: 0.5 mg flupentixol and 10 mg melitracen, film-coated tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test treatment: flupentixol/melitracen
Description: 0.5 mg flupentixol and 10 mg melitracen, film-coated tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference treatment: flupentixol/melitracen
Description: 0.5 mg flupentixol and 10 mg melitracen, coated tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference treatment: flupentixol/melitracen
Description: 0.5 mg flupentixol and 10 mg melitracen, coated tablet, single dose
Study: NCT04305418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness- Based Intervention
Description: Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment.
Study: NCT02639546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
Study: NCT01143649

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: constraint induced movement therapy (CIMT)
Study: NCT00387465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: 7mg by mouth (PO) on days 3 and 10 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine 40mg/m2
Description: Azacitidine 40mg/m2 SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine 40mg/m2
Description: Azacitidine 40mg/m2 SQ
Study: NCT01143649

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: constraint induced movement therapy (CIMT)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial alternating current stimulation (tACS)
Description: Subjects will be stimulated at 15Hz for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: Subjects will be stimulated at 15Hz for 20 minutes.
Study: NCT00159796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine, 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine, 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, 3 weeks
Study: NCT02685033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 4 m
Description: Oral alprazolam 4 mg + Inhaled placebo
Study: NCT02685033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Study: NCT02639546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
Study: NCT03121963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: oxycodone tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: acetaminophen tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: gabapentin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone-Acetaminophen
Description: hydrocodone 5 mg/acetaminophen 325 mg tablet
Study: NCT01390402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 130 mg/ m2 by vein for 2 doses on Days -11 to -10.
Study: NCT00603980

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 4 m
Description: Oral alprazolam 4 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 4 m
Description: Oral alprazolam 4 mg + Inhaled placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Oral alprazolam 4 m
Description: Oral alprazolam 4 mg + Inhaled placebo
Study: NCT01390402

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NK cell infusion:
Description: Natural killer cell infusion will be administered by vein on Day -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
Study: NCT00225563

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record
Description: e-prescribing methods
Study: NCT00585260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mannitol
Description: indirect mannitol challenge
Study: NCT01390402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: 2.5 mg/kg by vein for 3 doses on Days -3 to -1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic related Stem Cell Transplant
Description: Allogeneic related stem cell transplant by vein on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 by vein Days 1, 3 and 6 post transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is \> 500 x 10/L for 3 consecutive days.
Study: NCT03121950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: The primary intervention is a dance class

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: the secondary intervention is listening to live music
Study: NCT04265703

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal jugular vein catheterization
Description: Catheterization of internal jugular vein with real-time (in-plane) method, with neutral neck position. Standard aseptic technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subclavian vein catheterization
Description: Catheterization of subclavian/axillary vein with infra-clavicular approach with real-time (in-plane) method, without shoulder retraction. Standard aseptic technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Innominate vein catheterization
Description: Catheterization of innominate vein with supra-clavicular approach with real-time (in-plane) method, with neutral shoulder position and no shoulder retraction. Standard aseptic technique.
Study: NCT02308137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Simon-2-stage design for domperidone futility
Study: NCT00798122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound
Description: intravascular ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: cardiac MRI